Financial Contrast: Collegium Pharmaceutical (NASDAQ:COLL) vs. ReNeuron Group (OTCMKTS:RNUGF)

ReNeuron Group (OTCMKTS:RNUGF) and Collegium Pharmaceutical (NASDAQ:COLL) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, dividends, profitability, valuation, analyst recommendations and institutional ownership.

Risk and Volatility

ReNeuron Group has a beta of -0.63, indicating that its stock price is 163% less volatile than the S&P 500. Comparatively, Collegium Pharmaceutical has a beta of 0.73, indicating that its stock price is 27% less volatile than the S&P 500.

Analyst Ratings

This is a summary of current recommendations for ReNeuron Group and Collegium Pharmaceutical, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ReNeuron Group	0	0	0	0	0.00
Collegium Pharmaceutical	0	1	3	2	3.17

Collegium Pharmaceutical has a consensus price target of $57.50, indicating a potential upside of 61.56%. Given Collegium Pharmaceutical’s stronger consensus rating and higher possible upside, analysts plainly believe Collegium Pharmaceutical is more favorable than ReNeuron Group.

Profitability

This table compares ReNeuron Group and Collegium Pharmaceutical’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
ReNeuron Group	N/A	N/A	N/A
Collegium Pharmaceutical	9.41%	95.18%	16.39%

Valuation & Earnings

This table compares ReNeuron Group and Collegium Pharmaceutical”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ReNeuron Group	N/A	N/A	N/A	N/A	N/A
Collegium Pharmaceutical	$780.57 million	1.48	$62.87 million	$2.04	17.45

Collegium Pharmaceutical has higher revenue and earnings than ReNeuron Group.

Summary

Collegium Pharmaceutical beats ReNeuron Group on 9 of the 9 factors compared between the two stocks.

About ReNeuron Group

ReNeuron Group plc researches, develops, and commercializes cell-based therapies in the United Kingdom. The company engages in the development of CTX stem cell therapy candidate for treating stroke disability; and human retinal progenitor cell therapy that is in Phase 2 clinical trial for treating retinitis pigmentosa, a blindness-causing disease. It also develops CTX-derived exosomes that are in the pre-clinical stage, which are Nano-sized vesicles secreted by stem cells. In addition, the company licenses ReNcell products. It has a collaboration agreement with University College London to conduct research into the generation of immune cells from induced pluripotent stem cells for anti-cancer cell therapies. The company was founded in 1997 and is headquartered in Pencoed, the United Kingdom.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.